Kymera Therapeutics (KYMR) Net Income towards Common Stockholders (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Net Income towards Common Stockholders of -$69.2 million for Q1 2026, down 5.57% year-over-year from -$73.3 million in Q1 2025, and up 20.4% quarter-over-quarter from -$87.0 million in Q4 2025.
Kymera Therapeutics (KYMR) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Net Income towards Common Stockholders for 8 consecutive years, with -$69.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 5.57% year-over-year to -$69.2 million; the TTM figure through Mar 2026 stood at -$315.0 million (down 30.77% YoY), while the FY2025 annual figure was -$311.4 million, down 39.08% from the prior year.
- Net Income towards Common Stockholders rose to -$69.2 million in Q1 2026 per KYMR's latest filing, from -$87.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$14.4 million in Q4 2023 and bottomed at -$168.5 million in Q1 2022.
- Historically, Net Income towards Common Stockholders has averaged -$61.1 million across 5 years, with a median of -$52.9 million in 2023.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 84.09% in 2022 and fell as far as 1188.61% in 2022.
- Kymera Therapeutics' Net Income towards Common Stockholders stood at -$34.9 million in 2022, then soared by 58.79% to -$14.4 million in 2023, then tumbled by 392.43% to -$70.8 million in 2024, then fell by 22.94% to -$87.0 million in 2025, then climbed by 20.4% to -$69.2 million in 2026.
- Business Quant data shows KYMR's Net Income towards Common Stockholders at -$69.2 million in Q1 2026, -$87.0 million in Q4 2025, and -$82.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | -61.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.21 Mn |
| Mar 31, 2026 | -69.23 Mn |
| Dec 31, 2025 | -86.98 Mn |
| Sep 30, 2025 | -82.18 Mn |
| Jun 30, 2025 | -76.61 Mn |
| Mar 31, 2025 | -65.58 Mn |
| Dec 31, 2024 | -70.75 Mn |
| Sep 30, 2024 | -62.49 Mn |
| Jun 30, 2024 | -42.06 Mn |
| Mar 31, 2024 | -48.56 Mn |
| Dec 31, 2023 | -14.37 Mn |
| Sep 30, 2023 | -52.87 Mn |
| Jun 30, 2023 | -38.80 Mn |
| Mar 31, 2023 | -40.93 Mn |
| Dec 31, 2022 | -34.87 Mn |
| Sep 30, 2022 | -43.00 Mn |
| Jun 30, 2022 | -40.26 Mn |
| Mar 31, 2022 | -168.49 Mn |
| Dec 31, 2021 | -34.03 Mn |
| Sep 30, 2021 | -270.29 Mn |